NCT00396110已完成不适用
Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 3,889
研究概览
简要总结
In this study the effect of the switch to rosuvastatin from another statin (fluvastatin, pravastatin, simvastatin, atorvastatin) was evaluated in high-risk patients with and without evident CHD and LDL-C ≥ 3.2 mmol/l. This was done in a large observational study (TARGET) representing daily practice. Primary end points analysis was the percentage of patients reaching the target of LDL-C < 3.2 mmol/l. Secondary outcomes were the changes of LDL-C, HDL-C, TC, Triglycerides (TG) and TC/HDL-C-ratio from baseline.
研究设计
- 研究类型
- Observational
- 观察模型
- Defined Population
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •High-risk patients with and without evident CHD who had LDL-C > 3.2 mmol/l and were treated at that moment with HMG-CoA-reductase inhibitor apart from rosuvastatin.
- •Patients were aged >18 years and <70 years (men) and < 75 years (women).
排除标准
- •Treatment with atorvastatin 40 or 80 mg or simvastatin 80 mg
- •Patients familiar with muscular pain, myopathy or liver function disorders (inclusive elevation of serum transaminases) and/or contra-indications for treatment with rosuvastatin
研究者
相似试验
招募中
4 期
Rosuvastatin versus Protease Inhibitor Switching for Hypercholesterolaemia in HIV-infected Adults.ACTRN12612000732886St. Vincent's Hospital, Sydney60
招募中
3 期
A clinical trial to investigate the efficiency of rosuvastatin in acute cardiomyopathy induced anthracyclineCardiomyopathyIRCT2016121213090N3Vice chancellor for research of Mazandaran University of Medical Sciences80
已完成
不适用
Efficacy of Low-dose (10 mg) Rosuvastatin in Korean 4 Statin Benefit Groups Per 2013 ACC/AHA GuidelineDyslipidemiasNCT03903029Seoul National University Hospital242
已完成
不适用
Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE)DiabetesHypercholesterolemiaCVAPeripheral Vascular DiseaseCoronary Heart DiseaseNCT00574782AstraZeneca2,660
已完成
3 期
COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome SubjectsMetabolic SyndromeNCT00654485AstraZeneca940